10.80
-0.60 (-5.26%)
| Previous Close | 11.40 |
| Open | 11.33 |
| Volume | 2,034,434 |
| Avg. Volume (3M) | 2,312,368 |
| Market Cap | 1,626,058,752 |
| Price / Book | 13.25 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -9.25 |
| Total Debt/Equity (MRQ) | 13.68% |
| Current Ratio (MRQ) | 2.33 |
| Operating Cash Flow (TTM) | -644.94 M |
| Levered Free Cash Flow (TTM) | -394.10 M |
| Return on Assets (TTM) | -129.99% |
| Return on Equity (TTM) | -316.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Biohaven Ltd. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.88 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 90.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Mar 2026 | 10,286,937 |
| Infinitum Asset Management, Llc | 31 Mar 2026 | 6,250,000 |
| Stempoint Capital Lp | 31 Mar 2026 | 3,188,982 |
| Knoll Capital Management, Llc | 31 Mar 2026 | 2,328,602 |
| 52 Weeks Range | ||
| Median | 30.00 (177.78%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 11 Mar 2026 | 30.00 (177.78%) | Buy | 10.46 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |